Company Overview - Phreesia (NYSE: PHR) provides software solutions for healthcare providers, focusing on registration, scheduling, payments, and clinical support [1] - The software enhances patient intake processes and improves overall patient experiences [1] Recent Performance - Prior to the Q3 2024 earnings report, Phreesia's stock price increased by 21.0% [1] Analyst Background - Dr. Duru, who has been blogging about financial markets since 2000, has extensive experience through various market cycles, including the dot-com bubble, financial crisis, and the coronavirus pandemic [1] - Dr. Duru's blog "One-Twenty Two" offers unique perspectives on financial markets, covering a range of topics including stocks, options, currencies, and Bitcoin [1] - The blog utilizes both technical and fundamental analysis for trading and investing strategies [1]

Phreesia (PHR) shares ended the last trading session 13.9% higher at $21.19. The jump came on an impressive volume with a higher-than-average number of shares changing hands in the session. This compares to the stock's 12.9% loss over the past four weeks.Phreesia scored a strong price increase, driven by investors’ optimism surrounding its impending fiscal 2025 third-quarter results, slated to be released on Dec. 9 after the closing bell. In the fiscal second quarter, Phreesia reached a crucial milestone by ...

Maskot Summary Following my coverage on Phreesia, Inc. (NYSE:PHR) in Jun'24, in which I recommended a buy rating due to my expectation that the business has no issues growing revenue at 20% given that client growth is still strong, this post is to provide an update on my thoughts on the business and stock. I remain buy-rated for PHR as the growth outlook remains solid. New logo adds remain on track to hit FY25 targets, and the increase in transaction size in the current pipeline lends credence to PHR's next ...

Core Insights - Phreesia reported revenue of $102.12 million for the quarter ended July 2024, a year-over-year increase of 19% and a surprise of +0.35% over the Zacks Consensus Estimate of $101.76 million [1] - The company posted an EPS of -$0.31, improving from -$0.68 a year ago, with an EPS surprise of +16.22% compared to the consensus estimate of -$0.37 [1] Revenue Metrics - Average healthcare services clients reached 4,169, slightly above the average estimate of 4,159 based on three analysts [3] - Patient payment volume was reported at $1.09 billion, below the average estimate of $1.13 billion from three analysts [4] - Average revenue per healthcare services client was $17.73 million, compared to the two-analyst average estimate of $18.20 million [5] Segment Revenue Performance - Subscription and related services revenue was $48.61 million, exceeding the average estimate of $47.93 million based on six analysts, representing a year-over-year change of +23.7% [6] - Network solutions revenue was $28.20 million, slightly above the six-analyst average estimate of $28.06 million, with a year-over-year change of +23.2% [7] - Payment processing fees revenue was $25.30 million, below the average estimate of $25.76 million from six analysts, reflecting a year-over-year change of +7.1% [8] Stock Performance - Phreesia shares have returned +4.5% over the past month, outperforming the Zacks S&P 500 composite's +3.6% change [8] - The stock currently holds a Zacks Rank 2 (Buy), indicating potential for outperformance in the near term [8]

Company Overview - Phreesia is a leading provider of comprehensive solutions that transform the healthcare experience by activating patients in their care[4] - The company empowers healthcare organizations to maximize efficiency, drive growth, and deliver great care with tools that transcend patient intake[4] - Phreesia serves more than 4,100 AHSCs (Average Healthcare Services Clients)[4,10] - The company facilitated over 150 million patient visits in Fiscal Year 2024[4] Financial Performance - Total revenue for the latest twelve months was $390 million[4] - The company experienced 22% total revenue growth in the latest 12 months[4] - Q2 Fiscal Year 2025 total revenue reached $102.1 million, a 19% year-over-year increase[21] - Adjusted EBITDA for Q2 Fiscal Year 2025 was $6.5 million[13,21] - The company processed over $4 billion in patient payments in the latest twelve months[4] Market Opportunity - Phreesia operates in a total addressable market (TAM) of approximately $10 billion[16] - The company estimates $95 billion addressable out-of-pocket spend in the United States[15] Future Outlook - The company projects FY2025 total revenue to be between $416 million and $426 million, representing a 17%-20% year-over-year growth[26] - Phreesia anticipates approximately 4,200 AHSCs by the end of FY2025[26] - The company expects approximately 4,500 AHSCs in FY2026[26]

Phreesia (PHR) came out with a quarterly loss of $0.31 per share versus the Zacks Consensus Estimate of a loss of $0.37. This compares to loss of $0.68 per share a year ago. These figures are adjusted for non-recurring items. This quarterly report represents an earnings surprise of 16.22%. A quarter ago, it was expected that this developer of health care software would post a loss of $0.51 per share when it actually produced a loss of $0.35, delivering a surprise of 31.37%. Over the last four quarters, the ...

Wall Street analysts expect Phreesia (PHR) to post quarterly loss of $0.37 per share in its upcoming report, which indicates a year-over-year increase of 45.6%. Revenues are expected to be $102.05 million, up 18.9% from the year-ago quarter. The consensus EPS estimate for the quarter has remained unchanged over the last 30 days. This represents how the covering analysts, as a whole, have reassessed their initial estimates during this timeframe. Prior to a company's earnings announcement, it is crucial to co ...

Core Viewpoint - Phreesia (PHR) shares have increased by 13.2% in the past four weeks, closing at $22.65, with a mean price target of $28.94 indicating a potential upside of 27.8% [1] Group 1: Price Targets and Analyst Consensus - The average of 16 short-term price targets ranges from a low of $23 to a high of $34, with a standard deviation of $2.57, suggesting a potential increase of 1.6% to 50.1% from the current price [6] - Analysts have shown strong agreement in revising earnings per share (EPS) estimates higher, which correlates with potential stock price increases [9] - The Zacks Rank for PHR is 2 (Buy), placing it in the top 20% of over 4,000 ranked stocks based on earnings estimates [10] Group 2: Limitations of Price Targets - Solely relying on price targets for investment decisions may lead to disappointing returns, as analysts' ability to set unbiased targets has been questioned [2][5] - Empirical research indicates that price targets often mislead investors rather than guide them accurately [7] - Analysts may set overly optimistic price targets due to business incentives, which can inflate expectations [11]

Core Insights - The correlation between earnings estimate revisions and stock price movements is significant, influenced by institutional investors who adjust their valuations based on these estimates [1][6][8] Company Overview: Phreesia - Phreesia has received an upgrade to a Zacks Rank 1 (Strong Buy), indicating a positive outlook for its earnings estimates [3][4] - The Zacks rating upgrade reflects an upward trend in earnings estimates, which is a critical factor affecting stock prices [3][5] - Analysts have raised their earnings estimates for Phreesia, with the Zacks Consensus Estimate increasing by 21.3% over the past three months [12] Earnings Outlook - Phreesia is expected to report earnings of -$1.16 per share for the fiscal year ending January 2025, representing a year-over-year change of 53.8% [7] - The rising earnings estimates suggest an improvement in Phreesia's underlying business, which could lead to higher stock prices as investors respond positively [5][15] Zacks Rating System - The Zacks Rank system classifies stocks based on earnings estimate revisions, with Zacks Rank 1 stocks historically generating an average annual return of +25% since 1988 [11] - The system maintains a balanced distribution of ratings, ensuring that only the top 5% of stocks receive a 'Strong Buy' rating, indicating superior earnings estimate revisions [13][15]

The investigation concerns whether Phreesia and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices. On May 30, 2024, Phreesia issued a press release announcing financial results for the first quarter of its fiscal year 2025. Among other items, Phreesia update its "revenue outlook for fiscal year 2025 to a range of $416 million to $426 million from a previous range of $424 million to $434 million." Phreesia advised that "[t]he updated revenue range ...